Mike’s work focuses on developing and optimizing novel RNA-guided nuclease and base editor therapeutics as part of the Technology Development team.
Prior to joining Life Edit Therapeutics, Mike was a postdoctoral fellow at The University of North Carolina at Chapel Hill where he used CRISPR-based techniques to investigate enhancer/super-enhancer gene regulation in triple-negative breast cancer.
Mike received his PhD in Medical Sciences – Genetics at the University of Florida where he studied the genetic/epigenetic mechanisms of Angelman syndrome.
.svg)
.svg)
To rewrite the future by curing disease, making any edit, anywhere.
To pave the way to faster, safer, gene editing therapeutics that cure disease and improve patient lives.
We’re guided by curiosity, rigor, and integrity. We believe in discovery and unlimited potential. We care about science and the lives of patients.
